Clinical Trials Directory

Trials / Terminated

TerminatedNCT00769873

Anticoagulation Post Laparoscopic Splenectomy

Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
35 (actual)
Sponsor
University of Alberta · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Splenic/portal vein thrombosis is an alarming complication of splenectomy. Retrospective studies in the literature have shown the incidence of symptomatic splenic/portal vein thrombosis to be between 0.7% (Rattner et al., 1993) to 8% (Winslow et al., 2002). This is a single-center, prospective, randomized study in subjects undergoing laparoscopic splenectomy. All participants will receive one dose of pre-operative low molecular weight heparin (Lovenox®) subcutaneously, 2 hours prior to surgery. Participants will be randomized pre-operatively to treatment or control group however the treatment allocation will not be revealed until the surgery is complete. Postoperatively, those assigned to the treatment group will receive 40 mg of Lovenox® subcutaneously once a day for 21 days; those in the control group will not. Patients with severe renal impairment will receive an adjusted dose of Lovenox® (30 mg subcutaneous dose daily). All patients will have a baseline abdominal Doppler ultrasound preoperatively and a second one done at 14 to 28 days post surgery to monitor for the presence of portal vein and/or splenic vein thrombosis. They will also have their lipase and liver function tests checked to correlate with the imaging findings.

Conditions

Interventions

TypeNameDescription
DRUGEnoxaparinLovenox 40mg SC daily (30mg SC daily if creatinine clearance \< 30) for 21 days

Timeline

Start date
2006-10-01
Primary completion
2009-04-01
Completion
2009-05-01
First posted
2008-10-09
Last updated
2009-06-24

Locations

2 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT00769873. Inclusion in this directory is not an endorsement.